SPECIALITY MEDICINES IPO

Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.
The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations products, which are available in various dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.
The company operates via two models: (a) contract manufacturing of finished formulations for international distribution, and (b) marketing and distribution of sourced specialty pharmaceutical products.
The company has expanded internationally with registered or pending products in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia. Its distribution network builds strong relationships across over 20 states in India and more than 35 countries worldwide world.
As of March 31, 2025, the company has 1 product registered overseas and 60 products in the registration process across 5 countries, generating revenue.
As of August 31, 2025, the company had a total of 18 permanent employees across various departments.